Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity
Y Zhou, ML Bosch, ML Salgaller - Journal of immunotherapy, 2002 - journals.lww.com
The immunotherapy of cancer is predicated on the belief that it is possible to generate a
clinically meaningful antitumor response that provides patient benefit, such as improvement …
clinically meaningful antitumor response that provides patient benefit, such as improvement …
Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA
C Milazzo, VL Reichardt, MR Müller… - Blood, The Journal …, 2003 - ashpublications.org
Current immunotherapeutic trials for patients with multiple myeloma (MM) focus on the
idiotype (Id) as a tumor-specific antigen for active immunization. To bypass the need for the …
idiotype (Id) as a tumor-specific antigen for active immunization. To bypass the need for the …
Respiratory virus nucleic acid vaccines
G Ciaramella, S Himansu - US Patent 11,103,578, 2021 - Google Patents
HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=
C2C [C@@ H](O) CC [C@] 2 (C)[C@@ H] 2 [C@@ H] 1 [C@@ H] 1CC [C@ H]([C@ H](C) …
C2C [C@@ H](O) CC [C@] 2 (C)[C@@ H] 2 [C@@ H] 1 [C@@ H] 1CC [C@ H]([C@ H](C) …
CAR T-cell bioengineering: single variable domain of heavy chain antibody targeted CARs
F Rahbarizadeh, D Ahmadvand, SM Moghimi - Advanced Drug Delivery …, 2019 - Elsevier
Redirecting the recognition specificity of T lymphocytes to designated tumour cell surface
antigens by transferring chimeric antigen receptor (CAR) genes is becoming an effective …
antigens by transferring chimeric antigen receptor (CAR) genes is becoming an effective …
Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas
JP Carralot, B Weide, O Schoor, J Probst… - Genetic Vaccines and …, 2005 - Springer
Background Anti-tumor vaccines targeting the entire tumor antigen repertoire represent an
attractive immunotherapeutic approach. In the context of a phase I/II clinical trial, we …
attractive immunotherapeutic approach. In the context of a phase I/II clinical trial, we …
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
45893552&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
45893552&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas
C Flores, C Pham, D Snyder, S Yang… - …, 2015 - Taylor & Francis
Adoptive cellular therapy (ACT) after lymphodepletive conditioning can induce dramatic
clinical responses, but this approach has been largely limited to melanoma due to a lack of …
clinical responses, but this approach has been largely limited to melanoma due to a lack of …
Formulation and delivery of PLGA microspheres
A De Fougerolles, KM Wood, P Valencia - US Patent 9,271,996, 2016 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
48610363&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
48610363&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
Modified polynucleotides encoding septin-4
T Chakraborty, A De Fougerolles - US Patent 9,149,506, 2015 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
Advances in dendritic cell-based vaccine of cancer
Dendritic cells (DCs) are potent antigen presenting cells that exist in virtually every tissue,
and from which they capture antigens and migrate to secondary lymphoid organs where …
and from which they capture antigens and migrate to secondary lymphoid organs where …